Yohimbine

Summary

Yohimbine (CHEMBL15245) is an approved small-molecule α-adrenergic antagonist (ATC G04BE04) targeting HTR5A, HTR7, and HTR1A; indicated across 10 conditions including erectile dysfunction and post-traumatic stress disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G04BE04
• Targets: 12 (HTR5A, HTR7, HTR1A…)
• Indications: 10 conditions
• Clinical trials: 20
• Chemistry: 354.4 Da · C21H26N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL15245
Name	Yohimbine
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	8969
ChEBI	CHEBI:10093
ATC	G04BE04
Molecular formula	C21H26N2O3
Molecular weight	354.4
InChIKey	BLGXFZZNTVWLAY-SCYLSFHTSA-N

SMILES: COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O

IUPAC name: methyl (1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate

ChEBI definition: An indole alkaloid with α2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.

Pharmacological roles (ChEBI): α-adrenergic antagonist, serotonergic antagonist, dopamine receptor D2 antagonist.

Also known as: Yohimbine, Yohimbinum, yohimbine, Yohimbinic acid, beta-yohimbine, SID46501178, SID90340710, SID144203570, SID170465467, YOHIMBINE, YOHIMBINE_RAUWOLSCINE, Yohmbine

Parent form; salt/anhydrous children: CHEMBL537669

Patent coverage: 3,830 distinct patent families (11,917 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 11,825 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR5A	5-HT5A receptor	Antagonist	5.3	0%	P47898
HTR7	5-HT7 receptor	Antagonist	5.6	0.8%	P34969
HTR1A	5-HT1A receptor	Antagonist	7.3	0%	P08908
ADRA2A	α2A-adrenoceptor	Antagonist	8.7	0.1%	P08913
ADRA2B	α2B-adrenoceptor	Antagonist	8.4	0.2%	P18089
ADRA2C	α2C-adrenoceptor	Antagonist	8.8	0%	P18825
HTR1B	5-HT1B receptor	Antagonist	7.6	0.2%	P28222
TAS2R2	TAS2R2	Agonist			Q50KZ9
HTR1D	5-HT1D receptor	Antagonist	7.7	0%	P28221
HTR1E	5-ht1e receptor	Antagonist	5.9	0%	P28566
HTR1F	5-HT1F receptor	Antagonist	7	0.1%	P30939
HTR2B	5-HT2B receptor	Antagonist	7.9	0.4%	P41595

Broader ChEMBL bioactivity targets: 43 (assay-derived). Sample: DNA topoisomerase 1, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 1B, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Histamine H2 receptor, Alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 1D, D(1A) dopamine receptor.

Bioactivity

ChEMBL activities: 210 potent at pChembl ≥ 5 of 220 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRB2	10.4	Ki	0.04	nM	CHEMBL_ACT_25553926
ADRA2C	9.6	Ki	0.25	nM	CHEMBL_ACT_25841768
ADRA2A	9.4	Ki	0.4	nM	CHEMBL_ACT_320441
ADRA2A	9.38	Ki	0.42	nM	CHEMBL_ACT_302388
ADRA2C	9.3	Ki	0.5	nM	CHEMBL_ACT_14738660
ADRA2C	9.3	Ki	0.5	nM	CHEMBL_ACT_15187871
P30545	9.22	Ki	0.6	nM	CHEMBL_ACT_320438
ADRA2A	9.22	Ki	0.6	nM	CHEMBL_ACT_320442
P19328	9.22	Ki	0.6	nM	CHEMBL_ACT_320443
ADRA2C	9.1	Ki	0.8	nM	CHEMBL_ACT_19150882
ADRA2C	9.06	Ki	0.88	nM	CHEMBL_ACT_1523021
ADRA2A	9.05	Ki	0.9	nM	CHEMBL_ACT_320430
P19328	9	Ki	1	nM	CHEMBL_ACT_320436
ADRA1B	8.96	Ki	1.1	nM	CHEMBL_ACT_320429
ADRA2B	8.94	Ki	1.16	nM	CHEMBL_ACT_19150877
ADRA2A	8.85	Ki	1.4	nM	CHEMBL_ACT_1523022
ADRA2C	8.81	Ki	1.55	nM	CHEMBL_ACT_25982810
ADRA1D	8.8	Ki	1.6	nM	CHEMBL_ACT_320426
ADRA2A	8.74	Ki	1.8	nM	CHEMBL_ACT_320431
P19328	8.7	Ki	2	nM	CHEMBL_ACT_1268453
ADRA2B	8.7	Ki	2	nM	CHEMBL_ACT_25841767
ADRA2C	8.7	Ki	2	nM	CHEMBL_ACT_25982807
ADRA2B	8.7	Ki	2.01	nM	CHEMBL_ACT_302389
ADRA2C	8.64	Ki	2.3	nM	CHEMBL_ACT_504038
ADRA2A	8.64	Ki	2.31	nM	CHEMBL_ACT_7792995
P19328	8.62	Ki	2.4	nM	CHEMBL_ACT_320445
ADRA2A	8.58	Ki	2.63	nM	CHEMBL_ACT_25982798
ADRA2A	8.52	Ki	3	nM	CHEMBL_ACT_25982795
ADRA2A	8.52	Ki	3	nM	CHEMBL_ACT_320432
ADRA2A	8.51	Ki	3.1	nM	CHEMBL_ACT_1268452

Target pathways

Aggregated over 12 target gene(s): HTR5A, HTR7, HTR1A, ADRA2A, ADRA2B, ADRA2C, HTR1B, TAS2R2, HTR1D, HTR1E, HTR1F, HTR2B.

Top Reactome pathways

23 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	11	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
Signaling by GPCR	11	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
Class A/1 (Rhodopsin-like receptors)	11	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
Amine ligand-binding receptors	11	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
GPCR ligand binding	11	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
GPCR downstream signalling	10	ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
Serotonin receptors	8	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
G alpha (i) signalling events	8	ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A
Hemostasis	3	ADRA2A, ADRA2B, ADRA2C
Adrenoceptors	3	ADRA2A, ADRA2B, ADRA2C
Adrenaline signalling through Alpha-2 adrenergic receptor	3	ADRA2A, ADRA2B, ADRA2C
G alpha (z) signalling events	3	ADRA2A, ADRA2B, ADRA2C
Platelet activation, signaling and aggregation	3	ADRA2A, ADRA2B, ADRA2C
Platelet Aggregation (Plug Formation)	3	ADRA2A, ADRA2B, ADRA2C
Metabolism	2	ADRA2A, ADRA2C
Integration of energy metabolism	2	ADRA2A, ADRA2C
Metabolism of proteins	2	ADRA2A, ADRA2C
Adrenaline,noradrenaline inhibits insulin secretion	2	ADRA2A, ADRA2C
Regulation of insulin secretion	2	ADRA2A, ADRA2C
Surfactant metabolism	2	ADRA2A, ADRA2C
G alpha (q) signalling events	1	HTR2B
G alpha (s) signalling events	1	HTR7
RHOBTB3 ATPase cycle	1	HTR7

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	11
signal transduction	11
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	8
chemical synaptic transmission	8
adenylate cyclase-activating G protein-coupled receptor signaling pathway	6
adenylate cyclase-inhibiting serotonin receptor signaling pathway	6
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	6
G protein-coupled serotonin receptor signaling pathway	4
vasoconstriction	4
regulation of vasoconstriction	4
regulation of behavior	4
smooth muscle contraction	3
positive regulation of cell population proliferation	3
epidermal growth factor receptor signaling pathway	3
negative regulation of norepinephrine secretion	3

Indications & clinical

Indications

10 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
erectile dysfunction	4	MONDO:0005362	EFO:0004234
post-traumatic stress disorder	2	MONDO:0005146	EFO:0001358
cocaine dependence	2	MONDO:0005186	EFO:0002610
opiate dependence	2	MONDO:0005530	EFO:0010702
type 2 diabetes mellitus	2	MONDO:0005148	MONDO:0005148
alcohol abuse	2	MONDO:0002046	MONDO:0007079
orthostatic hypotension	1	MONDO:0005469	EFO:0005252
cannabis dependence	1	MONDO:0005689	EFO:0007191
postural orthostatic tachycardia syndrome	1	MONDO:0011479	EFO:1000645
Parkinson disease	0	MONDO:0005180	MONDO:0005180

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE2	7
Not specified	7
PHASE1	3
PHASE4	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00975325	PHASE4	COMPLETED	Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine
NCT06018727	PHASE4	WITHDRAWN	Role Of Sensitivity to neuroEndocrine Systems in Social Decisions
NCT04231708	PHASE2	NOT_YET_RECRUITING	Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder
NCT00535002	PHASE2	COMPLETED	The Effect of Yohimbine on Cocaine Cue Reactivity
NCT00605904	PHASE2	COMPLETED	Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics
NCT01031979	PHASE2	COMPLETED	Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With/Without Yohimbine
NCT01593215	PHASE2	COMPLETED	Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant
NCT04180969	PHASE2	WITHDRAWN	rTMS of Limbic Circuitry in Stress Modulation in Healthy Volunteers
NCT04181515	PHASE2	WITHDRAWN	Using rTMS to Explore Neural Mechanisms of Stress-Induced Opioid Use
NCT00223691	PHASE1	COMPLETED	Treatment of Orthostatic Hypotension in Autonomic Failure
NCT00748059	PHASE1	COMPLETED	The Pathophysiology of Orthostatic Hypotension
NCT03154567	PHASE1	COMPLETED	Effects of Stress and Drug-cue Exposure (SCM)
NCT02963181	EARLY_PHASE1	TERMINATED	Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension
NCT00029627	Not specified	COMPLETED	Brain Receptors in Sympathetic Nervous System Regulation
NCT00032838	Not specified	COMPLETED	Effects of Stress Hormones on Emotion and Cognition
NCT01621620	Not specified	UNKNOWN	The Role of Sympatho-vagal Balance on Different Limbs of Pain Perception in Healthy Subjects
NCT02470026	Not specified	COMPLETED	Noradrenergic Activity, Cognition and Major Depressive Disorder
NCT02541071	Not specified	COMPLETED	Influence of the Noradrenergic System on the Formation of Intrusive Memories
NCT04359147	Not specified	COMPLETED	The Role of Stress Neuromodulators in Decision Making Under Risk and Selective Attention to Threat
NCT06939608	Not specified	COMPLETED	Kinetics of Yohimbine in Humans to Explore Sex and CYP2D6 Genotype Interactions

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

817 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
Dihydroergotamine	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
RISPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
BREXPIPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR1E, HTR2B, HTR5A, HTR7
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
ERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A
IMIPRAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
Cyproheptadine	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
Pramipexole	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1E, HTR2B, HTR5A, HTR7
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2B, HTR5A, HTR7
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2B, HTR5A, HTR7
NEFAZODONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2B, HTR5A, HTR7
QUETIAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1E, HTR1F, HTR2B, HTR7
SUMATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1D, HTR2B, HTR5A, HTR7
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR1E, HTR2B, HTR7
KETANSERIN	ChEMBL	Phase 4 (approved)	ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2B, HTR5A, HTR7
SILODOSIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2B, HTR7
VILAZODONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2B, HTR7
SEROTONIN	ChEMBL + PubChem	Phase 3 (approved)	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
LATREPIRDINE	ChEMBL	Phase 3	ADRA2A, ADRA2B, ADRA2C, HTR1D, HTR1E, HTR2B, HTR5A, HTR7
MEBUFOTENIN	ChEMBL	Phase 2	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
RITANSERIN	ChEMBL	Phase 2	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1E, HTR5A, HTR7
AMOXAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR5A, HTR7
CHLORPROMAZINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR5A, HTR7
Cinacalcet	ChEMBL + PubChem	Phase 4 (approved)	ADRA2B, ADRA2C, HTR1A, HTR1D, HTR2B, HTR5A, HTR7
DOXEPIN	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR5A, HTR7
HALOPERIDOL	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR5A, HTR7
LOXAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR5A, HTR7
METHYLERGONOVINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1E, HTR1F, HTR2B
RIZATRIPTAN	ChEMBL + PubChem	Phase 4 (approved)	ADRA2C, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B
ZIPRASIDONE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1E, HTR2B, HTR7
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR5A, HTR7
MIANSERIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1D, HTR2B, HTR7
OXYMETAZOLINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2B
PRAZOSIN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1D, HTR2B, HTR5A
PROMAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR5A, HTR7
XYLOMETAZOLINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR1D, HTR2B
NIGULDIPINE	ChEMBL	Phase 2	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1B, HTR5A, HTR7
PENFLURIDOL	ChEMBL	Phase 2	ADRA2B, ADRA2C, HTR1A, HTR1D, HTR2B, HTR5A, HTR7
PSILOCIN	ChEMBL	Phase 2	HTR1A, HTR1B, HTR1D, HTR1E, HTR2B, HTR5A, HTR7
SPIPERONE	ChEMBL	Phase 2	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR5A, HTR7
SPIRAMIDE	ChEMBL	Phase 2	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1D, HTR2B, HTR7
ASENAPINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR1E, HTR2B
Candesartan Cilexetil	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR5A
HYDROXYZINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR2B, HTR5A, HTR7
Lasmiditan	ChEMBL + PubChem	Phase 4 (approved)	HTR1D, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR7
SORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	HTR1A, HTR1E, HTR1F, HTR2B, HTR5A, HTR7
TAMSULOSIN	ChEMBL + PubChem	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR7
CARVEDILOL	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR7
CISAPRIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR7
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR7
IPRINDOLE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR5A
KETOTIFEN	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR2B, HTR7
LURASIDONE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR7
METHYSERGIDE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR7
MIRTAZAPINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR7
PERPHENAZINE	ChEMBL	Phase 4 (approved)	ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B, HTR7
SALMETEROL	ChEMBL	Phase 4 (approved)	ADRA2B, HTR1A, HTR1B, HTR1D, HTR2B, HTR7